Understanding how skin and blood cell signals affect treatment response in children with dermatomyositis
Harnessing cutaneous transcriptional and myeloid cell signatures to understand treatment response in juvenile dermatomyositis
This study is looking at why some kids with juvenile dermatomyositis don’t get better with usual treatments by checking their skin and blood for clues, so we can find better ways to help them feel better.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11077252 on NIH RePORTER |
What this research studies
This research focuses on juvenile dermatomyositis (JDM), a serious autoimmune disease in children that can cause skin inflammation and muscle weakness. The study aims to explore the genetic and cellular signals in the skin and blood of affected children to identify why many do not respond to standard treatments. By analyzing these signals, researchers hope to uncover new biomarkers that can predict treatment outcomes and guide more effective therapies. The approach involves non-invasive skin sampling and detailed analysis of gene expression patterns over time.
Who could benefit from this research
Good fit: Ideal candidates for this research are children aged 0-11 years diagnosed with juvenile dermatomyositis.
Not a fit: Patients with juvenile dermatomyositis who are already receiving effective treatment and show no signs of treatment resistance may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies and better outcomes for children suffering from juvenile dermatomyositis.
How similar studies have performed: Previous research has shown promise in using molecular signatures to understand autoimmune diseases, suggesting that this approach could yield valuable insights.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Turnier, Jessica Leigh — University of Michigan at Ann Arbor
- Study coordinator: Turnier, Jessica Leigh
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.